Epidermal growth factor receptor signaling in nonsmall cell lung cancer

Cancer Investigation

Volumn 28, Issue 5, 2010, Pages 515-525

  Ganti, Apar Kishor ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Cetuximab; EGFR; Erlotinib; Gefitinib; Lung cancer

Indexed keywords

CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; K RAS PROTEIN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MOTESANIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; TOPOTECAN; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG;

ADD ON THERAPY; ANGIOGENESIS; ANOREXIA; APOPTOSIS; ARTICLE; ASIAN; ASTHENIA; BACKACHE; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CELL SURFACE; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG ERUPTION; DRUG POTENTIATION; DYSPNEA; ENZYME ACTIVATION; FATIGUE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; SIGNAL TRANSDUCTION; SMOKING; STOMATITIS; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77952117768     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903476760     Document Type: Article

References (138)

1. Herbst, R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004, 59, 21-26.
2. Carpenter, G.; Cohen, S. Epidermal growth factor. Annu Rev Biochem 1979, 48, 193-216.
3. Carpenter, G.; Cohen, S. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 1976, 71, 159-171.
4. Glover, K.Y.; Perez-Soler, R.; Papadimitradopoulou, V.A. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004, 31, 83-92.
5. Hunter, T.; Cooper, J.A. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981, 24, 741-752.
6. Vlahovic, G.; Crawford, J. Activation of tyrosine kinases in cancer. Oncologist 2003, 8, 531-538.
7. Veale, D.; Ashcroft, T.; Marsh, C.; Gibson, G.J.; Harris, A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987, 55, 513-516.
8. Sobol, R.E.; Astarita, R.W.; Hofeditz, C.; Masui, H.; Fairshter, R.; Royston, I.; Mendelsohn, J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987, 79, 403-407.
9. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19,183-232.
10. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A., Jr.; Di Maria, M.V.; Veve, R.; Bremmes, R.M.; Baron, A.E.; Zeng, C.; Franklin, W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21, 3798-3807.
11. Moscatello, D.K.; Holgado-Madruga, M.; Godwin, A.K.; Ramirez, G.; Gunn, G.; Zoltick, P.W.; Biegel, J.A.; Hayes, R.L.; Wong, A.J. Frequent expression of amutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55, 5536-5539.
12. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by G-proteincoupled receptors requiresmetalloproteinase cleavage of proHBEGF. Nature 1999, 402, 884-888.
13. Liu, D.; Aguirre Ghiso, J.; Estrada, Y.; Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1, 445-457.
14. El-Rayes, B.F.; LoRusso, P.M. Targeting the epidermal growth factor receptor. Br J Cancer 2004, 91, 418-424.
15. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82,241-250.
16. Yarden, Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl. 4), S3-S8.
17. Oda, K.; Matsuoka, Y.; Funahashi, A.; Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005, 1, 2005.0010.
18. Lowenstein, E.J.; Daly, R.J.; Batzer, A.G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E.Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70, 431-442.
19. Nagai, Y.; Miyazawa, H.; Huqun, Tanaka, T.; Udagawa, K.; Kato, M.; Fukuyama, S.; Yokote, A.; Kobayashi, K.; Kanazawa, M.; Hagiwara, K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65, 7276-7282.
20. von Eyben, F.E. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 2006, 43, 291-323.
21. Hartl, M.; Bader, A.G.; Bister, K. Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 2003, 3, 41-55.
22. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M.J.; Moyer, M.P.; Neveu, M.; Pollack, V.A.; Pustilnik, L.R.; Reynolds, M.M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57, 4838-4848.
23. Wu, X.; Fan, Z.; Masui, H.; Rosen, N.; Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995, 95, 1897-1905.
24. Wu, X.; Rubin, M.; Fan, Z.; DeBlasio, T.; Soos, T.; Koff, A.;Mendelsohn, J. Involvement of p27KIP1 in G1 arrest mediated by an antiepidermal growth factor receptor monoclonal antibody.Oncogene 1996, 12, 1397-1403.
25. Peng, D.; Fan, Z.; Lu, Y.; DeBlasio, T.; Scher, H.; Mendelsohn, J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996, 56, 3666-3669.
26. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9, 667-676.
27. Bellacosa, A.; Chan, T.O.; Ahmed, N.N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17, 313-325.
28. Sordella, R.; Bell, D.W.; Haber, D.A.; Settleman, J. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
29. Tracy, S.; Mukohara, T.; Hansen, M.; Meyerson, M.; Johnson, B.E.; Janne, P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004, 64, 7241-7244.
30. Duronio, V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008, 415, 333-344.
31. Perry, J.E.; Grossmann, M.E.; Tindall, D.J. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998, 35, 117-124.
32. Wang, Q.; Greene, M.I. EGFR enhances survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 2005, 79, 100-107.
33. Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396, 580-584.
34. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58, 5315-5320.
35. Carvalho, A.; Carmena, M.; Sambade, C.; Earnshaw, W.C.; Wheatley, S.P. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003, 116, 2987-2998.
36. Temme, A.; Rieger, M.; Reber, F.; Lindemann, D.; Weigle, B.; Diestelkoetter-Bachert, P.; Ehninger, G.; Tatsuka, M.; Terada, Y.; Rieber, E.P. Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 2003, 14, 78-92.
37. Uren, A.G.; Wong, L.; Pakusch, M.; Fowler, K.J.; Burrows, F.J.; Vaux, D.L.; Choo, K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000, 10, 1319-1328.
38. Kulik, G.; Klippel, A.; Weber, M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997, 17, 1595-1606.
39. Nagane, M.; Coufal, F.; Lin, H.; Bogler,O.; Cavenee,W.K.; Huang, H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996, 56, 5079-5086.
40. Karnes, W.E., Jr.; Weller, S.G.; Adjei, P.N.; Kottke, T.J.; Glenn, K.S.; Gores, G.J.; Kaufmann, S.H. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells.Gastroenterology 1998, 114, 930-939.
41. Modjtahedi, H.; Affleck, K.; Stubberfield, C.; Dean, C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998, 13, 335-342.
42. Uckun, F.M.; Narla, R.K.; Jun, X.; Zeren, T.; Venkatachalam, T.; Waddick, K.G.; Rostostev, A.; Myers, D.E. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 1998, 4, 901-912.
43. He, Y.; Zeng, Q.; Drenning, S.D.; Melhem, M.F.; Tweardy, D.J.; Huang, L.; Grandis, J.R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998, 90, 1080-1087.
44. Shao, H.; Cheng, H.Y.; Cook, R.G.; Tweardy, D.J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003, 63, 3923-3930.
45. Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421.
46. Goldman, C.K.; Kim, J.; Wong, W.L.; King, V.; Brock, T.; Gillespie, G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4, 121-133.
47. Folkman, J. Angiogenesis and its inhibitors. Important Adv Oncol 1985, 42-62.
48. Grotendorst, G.R.; Soma, Y.; Takehara, K.; Charette, M. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989, 139, 617-623.
49. de Jong, J.S.; van Diest, P.J.; van der Valk, P.; Baak, J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 1998, 184, 44-52.
50. Petit, A.M.; Rak, J.; Hung, M.C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151, 1523-1530.
51. Rosen, E.M.; Goldberg, I.D. Protein factors which regulate cell motility. In Vitro Cell Dev Biol 1989, 25, 1079-1087.
52. Price, J.T.; Wilson, H.M.; Haites, N.E. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 1996, 32A, 1977-1982.
53. Shibata, T.; Kawano, T.; Nagayasu, H.; Okumura, K.; Arisue, M.; Hamada, J.; Takeichi, N.; Hosokawa, M. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 1996, 17, 168-175.
54. Verbeek, B.S.; Adriaansen-Slot, S.S.; Vroom, T.M.; Beckers, T.; Rijksen, G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998, 425, 145-150.
55. Turner, T.; Chen, P.; Goodly, L.J.; Wells, A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 1996, 14, 409-418.
56. Watabe, T.; Yoshida, K.; Shindoh, M.; Kaya, M.; Fujikawa, K.; Sato, H.; Seiki, M.; Ishii, S.; Fujinaga, K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998, 77, 128-137.
57. Yasui, W.; Sumiyoshi, H.; Hata, J.; Kameda, T.; Ochiai, A.; Ito, H.; Tahara, E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988, 48, 137-141. (Pubitemid 18030342)
58. Yonemura, Y.; Takamura, H.; Ninomiya, I.; Fushida, S.; Tsugawa, K.; Kaji, M.; Nakai, Y.; Ohoyama, S.; Yamaguchi, A.; Miyazaki, I. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992, 49, 157-161.
59. Prakash, I.; Mathur, R.P.; Kar, P.; Ranga, S.; Talib, V.H. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J Pathol Microbiol 1997, 40, 481-490.
60. Parker, C.; Roseman, B.J.; Bucana, C.D.; Tsan, R.; Radinsky, R. Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J Histochem Cytochem 1998, 46, 595-602.
61. Radinsky, R.; Risin, S.; Fan, D.; Dong, Z.; Bielenberg, D.; Bucana, C.D.; Fidler, I.J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995, 1, 19-31.
62. Kurie, J.M.; Shin, H.J.; Lee, J.S.; Morice, R.C.; Ro, J.Y.; Lippman, S.M.; Hittelman, W.N.; Yu, R.; Lee, J.J.; Hong, W.K.. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996, 2, 1787-1793.
63. Franklin, W.A.; Veve, R., Hirsch, F.R., Helfrich, B.A., Bunn, P.A., Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29, 3-14.
64. Bunn, P.A., Jr.; Franklin, W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002, 29, 38-44.
65. Fujino, S.; Enokibori, T.; Tezuka, N.; Asada, Y.; Inoue, S.; Kato, H.; Mori, A. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996, 32A, 2070-2074.
66. Pavelic, K.; Banjac, Z.; Pavelic, J.; Spaventi, S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993, 13, 1133-1137.
67. Veale, D.; Kerr, N.; Gibson, G.J.; Kelly, P.J.; Harris, A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68, 162-165.
68. Volm, M.; Rittgen, W.; Drings, P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998, 77,663-669.
69. Brabender, J.; Danenberg, K.D.; Metzger, R.; Schneider, P.M.; Park, J.; Salonga, D.; Holscher, A.H.; Danenberg, P.V. Epidermal growth factor receptor and HER2-neu mRNA expression in nonsmall cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7, 1850-1855.
70. Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P.W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3, 515-522.
71. Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J.A.; Wolf, M.K.; Krebs, A.D.; Averbuch, S.D.; Ochs, J.S.; Grous, J.; Fandi, A.; Johnson, D.H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22, 785-794. (Pubitemid 41103589)
72. Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.;Miller, V.; Natale, R.B.; Schiller, J.H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J.S.; Averbuch, S.D.; Wolf, M.K.; Rennie, P.; Fandi, A.; Johnson, D.H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22, 777-784. (Pubitemid 41103588)
73. Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; Brannigan, B.W.; Sgroi, D.C.; Muir, B.; Riemenschneider, M.J.; Iacona, R.B.; Krebs, A.D.; Johnson, D.H.; Giaccone, G.; Herbst, R.S.; Manegold, C.; Fukuoka, M.; Kris, M.G.; Baselga, J.; Ochs, J.S.; Haber, D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23, 8081-8092.
74. Nakamura, H.; Kawasaki, N.; Taguchi, M.; Kabasawa, K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61, 140-145.
75. Dubey, S.; Stephenson, P.; Levy, D.E.; Miller, J.A.; Keller, S.M.; Schiller, J.H.; Johnson, D.H.; Kolesar, J.M. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006, 1, 406-412.
76. Hirsch, F.R. EGFR: a prognostic and/or a predictive marker? J Thorac Oncol 2006, 1, 395-397.
77. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
78. Sasaki, H.; Shimizu, S.; Endo, K.; Takada, M.; Kawahara, M.; Tanaka, H.; Matsumura, A.; Iuchi, K.; Haneda, H.; Suzuki, E.; Kobayashi, Y.; Yano, M.; Fujii, Y. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118, 180-184. (Pubitemid 41681596)
79. Ganti, A.K.; Potti, A. Epidermal growth factor inhibition in solid tumours. Expert Opin Biol Ther 2005, 5, 1165-1174.
80. Sato, J.D.; Kawamoto, T.; Le, A.D.; Mendelsohn, J.; Polikoff, J.; Sato, G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1, 511-529.
81. Lichtner, R.B.; Menrad, A.; Sommer, A.; Klar, U.; Schneider, M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61, 5790-5795.
82. Yamazaki, H.; Kijima, H.; Ohnishi, Y.; Abe, Y.; Oshika, Y.; Tsuchida, T.; Tokunaga, T.; Tsugu, A.; Ueyama, Y.; Tamaoki, N.; Nakamura, M. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 1998, 90, 581-587.
83. Ciardiello, F.; Caputo, R.; Troiani, T.; Borriello, G.; Kandimalla, E.R.; Agrawal, S.; Mendelsohn, J.; Bianco, A.R.; Tortora, G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001, 93, 172-178.
84. Masui, H.;Moroyama, T.;Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1986, 46, 5592-5598.
85. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8, 3-9.
86. Yang, X.D.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G.; Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59, 1236-1243.
87. Fan, Z.; Baselga, J.; Masui, H.; Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53, 4637-4642.
88. Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6, 701-708.
89. Sirotnak, FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003, 30, 12-20.
90. Judde, J.G.; Rebucci, M.; Vogt, N.; de Cremoux, P.; Livartowski, A.; Chapelier, A.; Tran-Perennou, C.; Boye, K.; Defrance, R.; Poupon, M.F.; Bras-Goncalves, R.A. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007, 120, 1579-1590.
91. Baselga, J.; Averbuch, S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000, 60(Suppl. 1), 33-40; discussion 41-132
92. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6, 2053-2063.
93. Sirotnak, F.M.; Zakowski, M.F.; Miller, V.A.; Scher, H.I.; Kris, M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6, 4885-4892.
94. Higgins, B.; Kolinsky, K.; Smith, M.; Beck, G.; Rashed, M.; Adames, V.; Linn, M.; Wheeldon, E.; Gand, L.; Birnboeck, H.; Hoffmann, G. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004, 15, 503-512.
95. Hidalgo, M. Erlotinib: preclinical investigations. Oncology (Williston Park) 2003, 17, 11-16.
96. Bianco, C.; Tortora, G.; Bianco, R.; Caputo, R.; Veneziani, B.M.; Caputo, R.; Damiano, V.; Troiani, T.; Fontanini, G.; Raben, D.; Pepe, S.; Bianco, A.R.; Ciardiello, F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8, 3250-3258.
97. Huang, S.M.; Li, J.; Armstrong, E.A.; Harari, P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002, 62, 4300-4306.
98. Hanna, N.; Lilenbaum, R.; Ansari, R.; Lynch, T.; Govindan, R.; Janne, P.A.; Bonomi, P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24, 5253-5258.
99. Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B.C.; Pfeifer, W.; O'Byrne, K.J.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M.R.; Ellis, P.A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19, 362-369.
100. Robert, F.; Blumenschein, G.; Herbst, R.S.; Fossella, F.V.; Tseng, J.; Saleh, M.N.; Needle, M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 9089-9096.
101. Thienelt, C.D.; Bunn, P.A., Jr.; Hanna, N.; Rosenberg, A.; Needle, M.N.; Long, M.E.; Gustafson, D.L.; Kelly, K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23, 8786-8793.
102. Belani, C.P.; Ramalingam, S.; Schreeder, M.; Steis, R.; Guidice, R.; Marshland, T.; Butler, B. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/ metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2007, 25, 7643.
103. Kim, E.S.; Mauer, A.M.; Fossella, F.V.; Jamison, T.A.; Kies, M.S.; Pisters, K.M.; Glisson, B.S.; Blumenschein Jr GR; Zinner, R.G.; Windt, P.; Liu, D.; Khuri, F.; Dicke, K.; Needle, M.; Vokes, E.E.; Hong, W.K.; Herbst, R.S. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21, 293a.
104. Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; Roh, J.K.; Bajetta, E.; O'Byrne, K.; de Marinis, F.; Eberhardt, W.; Goddemeier, T.; Emig, M.; Gatzemeier, U. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008, 26, 3.
105. Crawford, J.; Sandler, A.B.; Hammond, L.A.; Schiller, J.; Belani, C.; Kozloff, M.; Johnson, D.; Fleishman, A.; Lee, S.; Takeshita, K. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2004, 22, 7083-.
106. Blumenschein, G.; Sandler, A.; O'Rourke, T.; McGreivy, J.; Sun, Y.-N.; Ye, Y.; Parson, M.; Stephenson, J.J. Safety and pharmacokinetics (PK) of AMG 706 with carboplatin/paclitaxel (C/P) and/or panitumumab for the treatment of patients with advanced nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2007, 2, S469.
107. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J., Jr.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003, 290, 2149-2158. (Pubitemid 37432975)
108. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003, 21, 2237-2246.
109. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
110. Mok, T.; Wu, Y.-L.; Thongprasert, S.; Yang, C.-H.; Chu, D.; Saijo, N.; Jiang, H.; Watkins, C.; Armour, A.; Fukuoka, M. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/ paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008, 19, viii1-viii4.
111. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.- L.; Li, L.-Y.;Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y.; Liao, M.-L.; Østerlind, K.; Reck, M.; Armour, A.A.; Shepherd, F.A.; Lippman, S.M.; Douillard, J.-Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet 2008, 372, 1809-1818.
112. Crino, L.; Cappuzzo, F.; Zatloukal, P.; Reck, M.; Pesek, M.; Thompson, J.C.; Ford, H.E.R.; Hirsch, F.R.; Varella-Garcia, M.; Ghiorghiu, S.; Duffield, E.L.; Armour, A.A.; Speake, G.; Cullen, M. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26, 4253-4260.
113. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353, 123-132. (Pubitemid 41058344)
114. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz, J.; Manikhas, G.M.; Von Pawel, J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007, 25, 1545-1552
115. Herbst, R.S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; Kris, M.G.; Tran, H.T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D.H.; Miller, V.A. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 5892-5899.
116. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350, 2129-2139.
117. Kubo, A.; Nakagawa, K.; Kashii, T.; Hirashima, T.; Sasaki, J.; Tanaka, K.; Sato, S.; Kurata, T.; Tamura, K.; Fukuoka, M. Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR- 1 with gefitinib sensitivity in patients with non-small cell lung cancer: results of West Japan thoracic oncology group trial (WJTOG0203A). J Thoracic Oncol 2007, 2, S323.
118. Toyooka, S.; Takano, T.; Kosaka, T.; Ichihara, S.; Fujiwara, Y.; Hotta, K.; Soh, J.; Kiura, K.; Yatabe, Y.; Ohe, Y.; Mitsudomi, T.; Date, H. The impact of EGFR mutation and smoking status on non-smallcell lung cancer patients treated with geftinib. J Thorac Oncol 2007, 2, S324.
119. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A., Jr.; Franklin, W.A.; Dziadziuszko, R.; Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J.R.; Ciuleanu, T.; von Pawel, J.;Watkins, C.; Flannery, A.; Ellison, G.; Donald, E.; Knight, L.; Parums, D.; Botwood, N.; Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24, 5034-5042. (Pubitemid 46631407)
120. Hirsch, F.R.; Varella-Garcia, M.; Cappuzzo, F.; McCoy, J.; Bemis, L.; Xavier, A.C.; Dziadziuszko, R.; Gumerlock, P.; Chansky, K.; West, H.; Gazdar, A.F.; Crino, L.; Gandara, D.R.; Franklin, W.A.; Bunn, P.A., Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18, 752-760. (Pubitemid 46523281)
121. Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353, 133-144.
122. Han, S.W.; Kim, T.Y.; Hwang, P.G.; Jeong, S.; Kim, J.; Choi, I.S.; Oh, D.Y.; Kim, J.H.; Kim, D.W.; Chung, D.H.; Im, S.A.; Kim, Y.T.; Lee, J.S.; Heo, D.S.; Bang, Y.J.; Kim, N.K. Predictive and prognostic impact of epidermal growth factor receptormutation in nonsmall- cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23, 2493-2501.
123. Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23,2513-2520.
124. Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I.; Kunitoh, H.; Shibata, T.; Sakiyama, T.; Yoshida, T.; Tamura, T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23, 6829-6837.
125. Liu, G.; Gurubhagavatula, S.; Zhou, W.; Wang, Z.; Yeap, B.Y.; Asomaning, K.; Su, L.; Heist, R.; Lynch, T.J.; Christiani, D.C. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008, 8, 129-138.
126. Potti, A.; Dressman, H.K.; Bild, A.; Riedel, R.F.; Chan, G.; Sayer, R.; Cragun, J.; Cottrill, H.; Kelley, M.J.; Petersen, R.; Harpole, D.; Marks, J.; Berchuck, A.; Ginsburg, G.S.; Febbo, P.; Lancaster, J.; Nevins, J.R. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12, 1294-1300.
127. Eberhard, D.A.; Giaccone, G.; Johnson, B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in nonsmall- cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26, 983-994.
128. Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Janne, P.A.; Joshi, V.A.; McCollum, D.; Evans, T.L.; Muzikansky, A.; Kuhlmann,
129. Cappuzzo, F.; Finocchiaro, G.; Metro, G.; Bartolini, S.; Magrini, E.; Cancellieri, A.; Trisolini, R.; Castaldini, L.; Tallini, G.; Crino, L. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 2006, 58, 31-45.
130. Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23, 2445-2459.
131. Wang, S.E.; Narasanna, A.; Perez-Torres, M.; Xiang, B.; Wu, F.Y.; Yang, S.; Carpenter, G.; Gazdar, A.F.; Muthuswamy, S.K.; Arteaga, C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10, 25-38.
132. Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Hwang, P.G.; Im, S.A.; Lee, K.H.; Kim, J.H.; Kim, D.W.; Heo, D.S.; Kim, N.K.; Chung, D.H.; Bang, Y.J. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12, 2538-2544.
133. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359, 1757-1765.
134. Guix, M.; Faber, A.C.; Wang, S.E.; Olivares, M.G.; Song, Y.; Qu, S.; Rinehart, C.; Seidel, B.; Yee, D.; Arteaga, C.L.; Engelman, J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118, 2609-2619.
135. Morgillo, F.; Woo, J.K.; Kim, E.S.; Hong, W.K.; Lee, H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66, 10100-10111.
136. Morgillo, F.; Kim, W.Y.; Kim, E.S.; Ciardiello, F.; Hong, W.K.; Lee, H.Y. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13, 2795-2803.
137. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
138. Maruyama, R.; Nishiwaki, Y.; Tamura, T.; Yamamoto, N.; Tsuboi, M.; Nakagawa, K.; Shinkai, T.; Negoro, S.; Imamura, F.; Eguchi, K.; Takeda, K.; Inoue, A.; Tomii, K.; Harada, M.; Masuda, N.; Jiang, H.; Itoh, Y.; Ichinose, Y.; Saijo, N.; Fukuoka, M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26, 4244-4252.